INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference
MWN-AI** Summary
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company specializing in inflammation and immunology, announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference, scheduled for May 20-21, 2025, at the InterContinental Barclay in New York City. The company will engage in a fireside chat format and offer one-on-one virtual meetings, with a presentation planned for 11:00 AM EDT.
INmune Bio focuses on leveraging the innate immune system to develop innovative treatments targeting chronic inflammation and cancer, embodied in its three distinct product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product line specifically aims to neutralize soluble TNF, which is associated with various diseases. Key candidates like XPro™ are currently in clinical trials to evaluate their effectiveness in treating Mild Alzheimer’s disease, Mild Cognitive Impairment, and treatment-resistant depression.
The Natural Killer Cell Priming Platform features INKmune®, designed to enhance the patient’s NK cells to combat residual disease in cancer patients, with ongoing trials for metastatic castration-resistant prostate cancer. The CORDStrom™ program utilizes pooled, allogeneic, human umbilical cord-derived mesenchymal stem cells and recently completed a trial focused on recessive dystrophic epidermolysis bullosa.
While INmune Bio is optimistic about its innovations and their potential for regulatory approval, it emphasizes that all clinical trials are in the early stages, and no outcomes are guaranteed. The company warns of several risks, including funding availability and regulatory hurdles, as outlined in its SEC filings. For additional information, interested parties can visit INmune Bio’s website, or reach out to their investor relations contacts.
MWN-AI** Analysis
**Market Analysis & Advice for INmune Bio Inc. Ahead of RBC Capital Markets Conference**
As INmune Bio Inc. (NASDAQ: INMB) prepares to present at the 2025 RBC Capital Markets Global Healthcare Conference, investors should closely consider the company's clinical-stage status and ongoing product pipeline, which focuses on the innate immune system to tackle pressing health issues, such as Alzheimer’s disease, depression, and cancer.
The presence at a high-profile conference is strategic for INmune Bio, as it offers an opportunity to engage with investors and potentially attract additional funding for their clinical trials. Their three product platforms—DN-TNF, INKmune®, and CORDStrom™—showcase a well-rounded emphasis on chronic inflammation and cancer treatment, aligning them with key trends in the biotech sector.
However, it’s crucial to note that these products are still in clinical trials, indicating a higher level of risk associated with investment in INmune Bio. The lack of FDA approval for their therapies means that uncertainties loom large, including the company's ability to secure necessary funding to progress these initiatives.
Investors should be cautious in their approach. While the potential for high returns exists if any of the therapies gain approval, the volatility associated with clinical trial outcomes can lead to significant price swings. A prudent strategy might involve taking a smaller position in INMB while monitoring clinical trial results and regulatory updates closely.
In summary, while INmune Bio represents an intriguing opportunity within the biotechnology space, the inherent risks necessitate a balanced and measured investment strategy. Individuals should remain aware of ongoing developments and consider broader market conditions and trends in biotech when making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BOCA RATON, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces that the Company will be presenting at the 2025 RBC Capital Markets Global Healthcare Conference on May 20-21, 2025, at the InterContinental Barclay NY.
2025 RBC Capital Markets Global Healthcare Conference
May 20-21, 2025
Format: Fireside Chat and 1-on-1 virtual meetings
Presentation Time: 11:00am EDT
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune® developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is currently in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom ™ , is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio’s product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer. To learn more, please visit www.inmunebio.com .
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. CORDstrom™, XPro1595 (XPro™), and INKmune®™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
David Moss
Co-founder and Chief Financial Officer
(561) 710-0512
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
FAQ**
What specific advancements or updates will INmune Bio Inc. (NASDAQ: INMB) share during their presentation at the 2025 RBC Capital Markets Global Healthcare Conference regarding their DN-TNF product platform?
How does INmune Bio Inc. (NASDAQ: INMB) plan to address potential risks and uncertainties highlighted in their recent forward-looking statements during the upcoming conference?
Can INmune Bio Inc. (NASDAQ: INMB) provide insights on the timelines and current status of their clinical trials for XPro™ and CORDStrom™ during the presentation at the RBC Capital Markets Conference?
What are the key milestones that INmune Bio Inc. (NASDAQ: INMB) aims to achieve in 2025, particularly concerning their product development in immunology and inflammation?
**MWN-AI FAQ is based on asking OpenAI questions about INmune Bio Inc. (NASDAQ: INMB).
NASDAQ: INMB
INMB Trading
-5.44% G/L:
$1.565 Last:
646,918 Volume:
$1.66 Open:
